Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01972152 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia
A Phase 2 study of Hypoglycemia, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01972152 is a Phase 2 study of Hypoglycemia that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 30 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01972152, a Phase 2 study of Hypoglycemia, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
Conditions Studied
Interventions
- DRUG G-Pen(TM) 1 mg
- DRUG Lilly Glucagon(TM) 1 mg
- DRUG G-Pen(TM) 0.5 mg
Study Locations (1)
Texas
- Texas Diabetes Institute, University Health System - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01972152
The ClinicalTrials.gov registry entry for NCT01972152 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 3 interventions - of which G-Pen(TM) 1 mg is the first listed.
NCT01972152 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01972152 about?
NCT01972152 is a clinical study titled "Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia". The purpose of this study is to demonstrate that G-Pen(TM) glucagon is comparable to Lilly Glucagon(TM) in terms of safety and efficacy, as a treatment for severe hypoglycemia, a complication of diabetes.
What is the current status of trial NCT01972152?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-10. Estimated completion is 2014-02.
What conditions does trial NCT01972152 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT01972152?
The interventions under investigation include: G-Pen(TM) 1 mg (DRUG), Lilly Glucagon(TM) 1 mg (DRUG), G-Pen(TM) 0.5 mg (DRUG).
Who is sponsoring clinical trial NCT01972152?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01972152 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients
COMPLETED · Phase 2
-
G-Pen™ for Hypoglycemia Rescue in T1D Patients
COMPLETED · Phase 2
-
External Carotid Blood Flow in Individuals With Post-Bariatric Hypoglycemia
RECRUITING
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.